SCHEMBL6314989

SCHEMBL6314989

Nc1onc(-c2ccncc2)c1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.49
LMNA P02545 1/20 0.48
RAB9A P51151 1/20 0.48
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MLYCD O95822 1/20 0.45
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
CA4 P22748 4/20 0.44
CA7 P43166 4/20 0.44
KMT2A Q03164 2/20 0.43
SRC P12931 2/20 0.43
KDR P35968 2/20 0.43
GAA P10253 2/20 0.43
MEN1 O00255 1/20 0.43
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
BRAF P15056 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314872 0.87 KMT2A (0.50) MAPK14LMNARAB9AMAPK1SMN1; SMN2
SCHEMBL13745059 0.82 RAB9A (0.69) LMNARAB9ACA1CA2CA4
SCHEMBL6315186 0.81 TDO2 (0.49) LMNASMN1; SMN2CA1CA2CA4
SCHEMBL6069148 0.80 SMN1; SMN2 (0.62) LMNARAB9AMAPK1SMN1; SMN2KMT2A
SCHEMBL6317187 0.80 IKBKB (0.43) LMNARAB9ACA1CA2CA4
SCHEMBL6620565 0.78 LMNA (0.47) MAPK14LMNARAB9AMAPK1SMN1; SMN2
SCHEMBL6317594 0.77 CA1 (0.48) LMNARAB9AMAPK1SMN1; SMN2CA1
SCHEMBL27610083 0.77 ALDH1A1 (0.51) MAPK14LMNARAB9AMAPK1SMN1; SMN2
SCHEMBL6316604 0.77 ALDH1A1 (0.57) MAPK1SMN1; SMN2CA1CA2CA4
SCHEMBL6316560 0.75 SMN1; SMN2 (0.59) RAB9AMAPK1SMN1; SMN2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPK14 111/4885LMNA 3334/4885RAB9A 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.